Founded in 2001, our group is a globally recognized Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in peptides and oligonucleotides. Our integrated service model is designed to support partners through the most critical phases of drug development, with a particular focus on late-phase development, large-scale manufacturing, and commercial production. From initial discovery to full commercialization, we provide the expertise and infrastructure to accelerate your peptide and oligonucleotide programs to success.

In June 2025, CPC Scientific’s parent company, Medtide Inc., was officially listed on the main board of the Hong Kong Stock Exchange, marking a major milestone that reflects our continued growth and global impact.

We focus on (i) contract research organization (“CRO”) services, including peptide new chemical entity (“NCE”) discovery synthesis; (ii) contract development and manufacturing organization (“CDMO”) services, including peptide chemistry, manufacturing, and controls (“CMC”) development; and (iii) contract manufacturing organization (“CMO”) services, including peptide NCE and generic drug commercial manufacturing. We have established global operations, with projects covering over 50 countries, including major markets in the United States, China, Japan, Europe, South Korea, and Australia. We also provide customers with peptide drug development, production, and CMC filing support services that meet regulatory requirements in major markets worldwide.

We are a full-service peptide-focused CRDMO with vertically integrated capabilities in peptide drug development and manufacturing. Given the increasing complexity of new peptide drugs, which makes the development and manufacturing of peptides a time- and capital-intensive process, our tailored services are ideally suited for pharmaceutical and biotechnology companies seeking outsourcing solutions for their development and manufacturing needs.

In addition to peptides, we have developed a diverse project pipeline focusing on various types of complex peptide- and oligonucleotide-based new chemical entities (“NCEs”). Our peptide conjugation services seamlessly integrate our peptide and oligonucleotide platforms to produce a wide range peptide conjugates products. Our integrated oligonucleotide and peptide platforms are dedicated to the development and large-scale manufacturing (i.e., kilogram-scale) of peptide-oligonucleotide conjugates (“POC”), peptide drug conjugates (“PDC”), and radionuclide drug conjugates (“RDC”).

Our global production facilities adhere strictly to Current Good Manufacturing Practice (CGMP) standards as mandated by the world’s leading regulatory authorities. We comply fully with the requirements of the U.S. Food and Drug Administration (FDA), National Medical Products Administration (NMPA), European Medicines Agency (EMA), Therapeutic Goods Administration (TGA), and Korean Ministry of Food and Drug Safety (MFDA). To demonstrate our commitment to quality and compliance, we have successfully passed five rigorous FDA inspections. Additionally, our facilities are certified with ISO 9001 and ISO 13485 for quality management systems, underscoring our dedication to delivering the highest standards of safety and efficacy in every product we manufacture.

With 19 peptide synthetic production suites equipped with reactor volumes ranging from 20 to 1,000 liters, and 16 purification suites with HPLC column sizes of up to 30 inches, our facilities boast an annual API production capacity over 1,000 kilograms, with a per-batch capacity over 25 kilograms. Additionally, we can accommodate multiple purchase orders at the 100-kilogram level. Recently, our facility has been reconfigured to facilitate the manufacturing of 1-17 kilograms of oligonucleotides annually.